New Leukemia Treatment
Last week saw the first treatment in the UK for B-cell acute lymphoblastic leukaemia, which involves filtering out the patient’s T-cells, and genetically altering these cells to express chimeric antigen receptors. These cells (known as CAR-T cells) are then grown in culture and introduced back into the patient’s bloodstream. This allows the patient’s own immune system to identify and destroy the cancerous B-cells present in the blood.
Clinical trials suggest that patients can go into remission and do not require a second gene therapy treatment even after 24 months, which indicates a potential long-term stabilisation of the condition post-treatment.
Read more, rate and review here:
Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel)
